About Pharming Group (NASDAQ:PHGUF)
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company's products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming's technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company's commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:PHGUF
- CUSIP: N/A
- Web: www.pharming.com/
- 52 Week Range: $0.17 - $0.98
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 43.50
- P/E Growth: 0.000
- Annual Revenue: $49.56 million
- Price / Sales: N/A
- Book Value: $0.02 per share
- Price / Book: 43.50
Frequently Asked Questions for Pharming Group (NASDAQ:PHGUF)
What is Pharming Group's stock symbol?
Pharming Group trades on the NASDAQ under the ticker symbol "PHGUF."
How were Pharming Group's earnings last quarter?
Pharming Group (NASDAQ:PHGUF) posted its quarterly earnings data on Thursday, March, 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. View Pharming Group's Earnings History.
When will Pharming Group make its next earnings announcement?
Who are some of Pharming Group's key competitors?
Some companies that are related to Pharming Group include Cardiovascular Systems (CSII), Anika Therapeutics (ANIK), Flexion Therapeutics (FLXN), Intersect ENT (XENT), K2M Group Holdings (KTWO), Intra-Cellular Therapies (ITCI), Amphastar Pharmaceuticals (AMPH), Akebia Therapeutics (AKBA), Reata Pharmaceuticals (RETA), U.S. Physical Therapy (USPH), Heron Therapeutics (HRTX), Abeona Therapeutics (ABEO), PetIQ (PETQ), BeyondSpring (BYSI), ZIOPHARM Oncology (ZIOP), China Cord Blood Corporation (CO), Revance Therapeutics (RVNC) and Cytokinetics, Incorporated (CYTK).
Who are Pharming Group's key executives?
Pharming Group's management team includes the folowing people:
- Paul Jai Sekhri, Chairman of the Board of Supervisory Directors
- Sijmen de Vries, Member of the Management Board, Chief Executive Officer
- Juergen H. L. Ernst, Vice Chairman of the Board of Supervisory Directors
- Robin Wright, Chief Financial Officer, Member of the Management Board
- Bruno M. Giannetti, Member of the Management Board, Chief Operations Officer
- Anne-Marie de Groot, Senior Vice President Organizational Development, Member of the Management Board
- Jaap Blaak, Member of the Board of Supervisory Directors
- Aad de Winter, Member of the Board of Supervisory Directors
- Jan H. Egberts M.D., Member of the Board of Supervisory Directors
- Jonh Barrie Ward Ph.D., Member of the Board of Supervisory Directors
How do I buy Pharming Group stock?
Shares of Pharming Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharming Group's stock price today?
MarketBeat Community Rating for Pharming Group (NASDAQ PHGUF)MarketBeat's community ratings are surveys of what our community members think about Pharming Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pharming Group stock can currently be purchased for approximately $0.87.
Consensus Ratings for Pharming Group (NASDAQ:PHGUF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Pharming Group (NASDAQ:PHGUF)
Analysts' Ratings History for Pharming Group (NASDAQ:PHGUF)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Pharming Group (NASDAQ:PHGUF)Earnings History by Quarter for Pharming Group (NASDAQ PHGUF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/26/2017|| || || || || || || || |
Earnings Estimates for Pharming Group (NASDAQ:PHGUF)
Current Year EPS Consensus Estimate: $-0.09 EPS
Next Year EPS Consensus Estimate: $0.02 EPS
Dividend History for Pharming Group (NASDAQ:PHGUF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Pharming Group (NASDAQ:PHGUF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Pharming Group (NASDAQ:PHGUF)
Latest Headlines for Pharming Group (NASDAQ:PHGUF)
Pharming Group (PHGUF) Chart for Saturday, October, 21, 2017